KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Deferred Taxes: 2013-2017

Historic Deferred Taxes for Travere Therapeutics (TVTX) over the last 5 years, with Dec 2017 value amounting to -$6.4 million.

  • Travere Therapeutics' Deferred Taxes rose 111.88% to $1.4 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$6.4 million, marking a year-over-year increase of 71.65%. This contributed to the annual value of -$6.4 million for FY2017, which is 71.65% up from last year.
  • Latest data reveals that Travere Therapeutics reported Deferred Taxes of -$6.4 million as of FY2017, which was up 71.65% from -$22.7 million recorded in FY2016.
  • In the past 5 years, Travere Therapeutics' Deferred Taxes ranged from a high of -$2.5 million in FY2014 and a low of -$22.7 million during FY2016.
  • Over the past 3 years, Travere Therapeutics' median Deferred Taxes value was -$15.6 million (recorded in 2015), while the average stood at -$14.9 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first surged by 74.71% in 2014, then plummeted by 533.05% in 2015.
  • Yearly analysis of 5 years shows Travere Therapeutics' Deferred Taxes stood at -$9.7 million in 2013, then surged by 74.71% to -$2.5 million in 2014, then tumbled by 533.05% to -$15.6 million in 2015, then slumped by 45.51% to -$22.7 million in 2016, then surged by 71.65% to -$6.4 million in 2017.